AI-generated summary
This review examines the use of intravitreal aflibercept, an anti-vascular endothelial growth factor agent, for diabetic macular oedema. The authors report greater visual acuity improvements to week 52 versus macular laser in the VISTA-DME and VIVID-DME trials, and versus bevacizumab or ranibizumab in patients with worse baseline vision in PROTOCOL-T. The authors describe the drug as generally well tolerated.
- Who or what was studied
- Patients with diabetic macular oedema
- Limits stated in the abstract
- The abstract does not report sample sizes or the number of studies reviewed, and it gives no details on the strength of the evidence or on adverse events.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on link.springer.com.
Record from PubMed, a service of the National Library of Medicine.
How to read a review: what to check before relying on this kind of research.
Terms in this paper: Laser. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.